Cascadian Therapeutics cascadianrx.com


Public list: BIO 2016 (619) Pharma Startups (4733) Cancer Therapeutics (1136)

Cascadian Therapeutics, fka Oncothyreon, is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer.

Cascadian Therapeutics, fka Oncothyreon, is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer.

Company (Acquired)

Phone: 206-801-2100

Fax:

3101 Western Ave
Suite 600
Seattle, 98121
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cascadian Therapeutics $10.2M Mar 9, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cascadian Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 20 investors

Board Members

There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Mucinous glycoprotein (muc-1) vaccine Apr 01, 2005 Nov 03, 2015 Patent
Method of treating patients with a mucinous glycoprotein (muc-1) vaccine Sep 17, 2014 Sep 01, 2015 Patent
Muc1 based glycolipopeptide vaccine with adjuvant Feb 23, 2012 Nov 18, 2014 Patent
Method of treating patients with a mucinous glycoprotein (muc-1) vaccine Jun 27, 2006 Oct 28, 2014 Patent
Vaccine for modulating between t1 and t2 immune responses May 02, 2012 Oct 08, 2013 Patent
See all 15 patents